A small molecule, odanacatib, inhibits inflammation and bone loss caused by endodontic disease

Infection and Immunity

Volumn 83, Issue 4, 2015, Pages 1235-1245

  Hao, Liang ^a,b   Chen, Wei ^b   McConnell, Matthew ^b   Zhu, Zheng ^b   Li, Sheng ^b   Reddy, Michael ^c   Eleazer, Paul D ^d   Wang, Min ^a   Li, Yi Ping ^b  

^a SICHUAN UNIVERSITY   (China)

^b University of Alabama at Birmingham   (United States)

^c Univ of Alabama School of Dentistry   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN K; INTERLEUKIN 23P19; INTERLEUKIN 6; ODANACATIB; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR ALPHA; BIPHENYL DERIVATIVE; CTSK PROTEIN, MOUSE; IL23A PROTEIN, MOUSE; MESSENGER RNA; TLR4 PROTEIN, MOUSE; TLR9 PROTEIN, MOUSE; TUMOR NECROSIS FACTOR;

ADAPTIVE IMMUNITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DENSITY; BONE DESTRUCTION; BONE EROSION; CD3+ T LYMPHOCYTE; CONTROLLED STUDY; ENZYME INHIBITION; GENE EXPRESSION; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; INFLAMMATORY DISEASE; MACROPHAGE; MALE; MICRO-COMPUTED TOMOGRAPHY; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOGRAPHY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TOOTH PERIAPICAL DISEASE; ALVEOLAR BONE LOSS; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; COMPLICATION; DENTAL CARIES; DISEASE MODEL; DRUG EFFECTS; GENETICS; IMMUNOLOGY; PERIAPICAL PERIODONTITIS; T LYMPHOCYTE;

ALVEOLAR BONE LOSS; ANIMALS; BIPHENYL COMPOUNDS; CATHEPSIN K; DENTAL CARIES; DISEASE MODELS, ANIMAL; INTERLEUKIN-23 SUBUNIT P19; INTERLEUKIN-6; MACROPHAGES; MALE; MICE; MICE, INBRED BALB C; OSTEOCLASTS; PERIAPICAL PERIODONTITIS; RNA, MESSENGER; T-LYMPHOCYTES; TOLL-LIKE RECEPTOR 4; TOLL-LIKE RECEPTOR 5; TOLL-LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84925379510     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.01713-14     Document Type: Article

References (44)

1. Wang QQ, Zhang CF, Chu CH, Zhu XF. 2012. Prevalence of Enterococcus faecalis in saliva and filled root canals of teeth associated with apical periodontitis. Int J Oral Sci 4:19-23. http://dx.doi.org/10.1038/ijos.2012.17.
2. Stashenko P, Teles R, D'Souza R. 1998. Periapical inflammatory responses and their modulation. Crit Rev Oral Biol Med 9:498-521. http://dx.doi.org/10.1177/10454411980090040701.
3. Jiang H, Chen W, Zhu G, Zhang L, Tucker B, Hao L, Feng S, Ci H, Ma J, Wang L, Stashenko P, Li YP. 2013. RNAi-mediated silencing of Atp6i and Atp6i haploinsufficiency prevents both bone loss and inflammation in a mouse model of periodontal disease. PLoS One 8:e58599. http://dx.doi.org/10.1371/journal.pone.0058599.
4. Yang S, Hao L, McConnell M, Zhou X, Wang M, Zhang Y, Mountz JD, Reddy M, Eleazer PD, Li YP, Chen W. 2013. Inhibition of Rgs10 expression prevents immune cell infiltration in bacteria-induced inflammatory lesions and osteoclast-mediated bone destruction. Bone Res 1:267-281. http://dx.doi.org/10.4248/BR201303005.
5. Eleazer PD, Farber PA, Seltzer S. 1975. Lack of lymphocyte stimulation by root canal products. J Endod 1:388-394. http://dx.doi.org/10.1016/S0099-2399(75)80157-9.
6. Duong LT. 2013. Inhibition of cathepsin K: blocking osteoclast bone resorption and more. IBMS BoneKEy 10:396. http://dx.doi.org/10.1038/bonekey.2013.130.
7. Troen BR. 2004. The role of cathepsin K in normal bone resorption. Drug News Perspect 17:19-28. http://dx.doi.org/10.1358/dnp.2004.17.1.829022.
8. Matsumoto F, Saitoh S-I, Fukui R, Kobayashi T, Tanimura N, Konno K, Kusumoto Y, Akashi-Takamura S, Miyake K. 2008. Cathepsins are required for Toll-like receptor 9 responses. Biochem Biophys Res Commun 367:693-699. http://dx.doi.org/10.1016/j.bbrc.2007.12.130.
9. Asagiri M, Hirai T, Kunigami T, Kamano S, Gober H-J, Okamoto K, Nishikawa K, Latz E, Golenbock DT, Aoki K, Ohya K, Imai Y, Morishita Y, Miyazono K, Kato S, Saftig P, Takayanagi H. 2008. Cathepsin K-dependent Toll-like receptor 9 signaling revealed in experimental arthritis. Science 319:624-627. http://dx.doi.org/10.1126/science.1150110.
10. Gao B, Chen W, Hao L, Zhu G, Feng S, Ci H, Zhou X, Stashenko P, Li YP. 2013. Inhibiting periapical lesions through AAV-RNAi silencing of cathepsin K. J Dent Res 92:180-186. http://dx.doi.org/10.1177/0022034512468757.
11. Li YP, Chen W. 1999. Characterization of mouse cathepsin K gene, the gene promoter, and the gene expression. J Bone Mineral Res 14:487-499. http://dx.doi.org/10.1359/jbmr.1999.14.4.487.
12. Walsh MC, Kim N, Kadono Y, Rho J, Lee SY, Lorenzo J, Choi Y. 2006. Osteoimmunology: interplay between the immune system and bone metabolism. Annu Rev Immunol 24:33-63. http://dx.doi.org/10.1146/annurev.immunol.24.021605.090646.
13. Takayanagi H. 2007. Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol 7:292-304. http://dx.doi.org/10.1038/nri2062.
14. Fleischmann R. 2012. Novel small-molecular therapeutics for rheumatoid arthritis. Curr Opin Rheumatol 24:335-341. http://dx.doi.org/10.1097/BOR.0b013e32835190ef.
15. Eisman JA, Bone HG, Hosking DJ, McClung MR, Reid IR, Rizzoli R, Resch H, Verbruggen N, Hustad CM, DaSilva C, Petrovic R, Santora AC, Ince BA, Lombardi A. 2011. Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect. J Bone Mineral Res 26:242-251. http://dx.doi.org/10.1002/jbmr.212.
16. Stoch SA, Zajic S, Stone J, Miller DL, Van Dyck K, Gutierrez MJ, De Decker M, Liu L, Liu Q, Scott BB, Panebianco D, Jin B, Duong LT, Gottesdiener K, Wagner JA. 2009. Effect of the cathepsin K inhibitor odanacatib on bone resorption biomarkers in healthy postmenopausal women: two double-blind, randomized, placebo-controlled phase I studies. Clin Pharmacol Ther 86:175-182. http://dx.doi.org/10.1038/clpt.2009.60.
17. Ma J, Chen W, Zhang L, Tucker B, Zhu G, Sasaki H, Hao L, Wang L, Ci H, Jiang H, Stashenko P, Li Y-P. 2013. RNA interference-mediated silencing of Atp6i prevents both periapical bone erosion and inflammation in the mouse model of endodontic disease. Infect Immun 81:1021-1030. http://dx.doi.org/10.1128/IAI.00756-12.
18. Feng S, Deng L, Chen W, Shao J, Xu G, Li YP. 2009. Atp6v1c1 is an essential component of the osteoclast proton pump and in F-actin ring formation in osteoclasts. Biochem J 417:195-203. http://dx.doi.org/10.1042/BJ20081073.
19. Sasaki H, Hou L, Belani A, Wang CY, Uchiyama T, Muller R, Stashenko P. 2000. IL-10, but not IL-4, suppresses infectionstimulated bone resorption in vivo. J Immunol 165:3626-3630. http://dx.doi.org/10.4049/jimmunol.165.7.3626.
20. Sasaki H, Okamatsu Y, Kawai T, Kent R, Taubman M, Stashenko P. 2004. The interleukin-10 knockout mouse is highly susceptible to Porphyromonas gingivalis-induced alveolar bone loss. J Periodontal Res 39:432-441. http://dx.doi.org/10.1111/j.1600-0765.2004.00760.x.
21. O'Neill LAJ, Golenbock D, Bowie AG. 2013. The history of Toll-like receptors-redefining innate immunity. Nat Rev Immunol 13:453-460. http://dx.doi.org/10.1038/nri3446.
22. Conus SSH. 2010. Cathepsins and their involvement in immune responses. Swiss Med Wkly 140:w13042. http://dx.doi.org/10.4414/smw.2010.13042.
23. Krieg AM, Lipford GB. 2008. Immunology: the toll of cathepsin K deficiency. Science 319:576-577. http://dx.doi.org/10.1126/science.1154207.
24. Owens RA. 2002. Second generation adeno-associated virus type 2-based gene therapy systems with the potential for preferential integration into AAVS1. Curr Gene Ther 2:145-159. http://dx.doi.org/10.2174/1566523024605627.
25. Spring DR. 2005. Chemical genetics to chemical genomics: small molecules offer big insights. Chem Soc Rev 34:472-482. http://dx.doi.org/10.1039/b312875j.
26. Yasuda Y, Kaleta J, Bromme D. 2005. The role of cathepsins in osteoporosis and arthritis: rationale for the design of new therapeutics. Adv Drug Deliv Rev 57:973-993. http://dx.doi.org/10.1016/j.addr.2004.12.013.
27. Vasiljeva O, Reinheckel T, Peters C, Turk D, Turk V, Turk B. 2007. Emerging roles of cysteine cathepsins in disease and their potential as drug targets. Curr Pharm Des 13:387-403. http://dx.doi.org/10.2174/1381612077 80162962.
28. Herroon MK, Rajagurubandara E, Rudy DL, Chalasani A, Hardaway AL, Podgorski I. 2013. Macrophage cathepsin K promotes prostate tumor progression in bone. Oncogene 32:1580-1593. http://dx.doi.org/10.1038/onc.2012.166.
29. Moller AJ. 1966. Microbiological examination of root canals and periapical tissues of human teeth. Methodological studies. Odontol Tidskr 74(Suppl):1-380.
30. Strand V, Kavanaugh AF. 2004. The role of interleukin-1 in bone resorption in rheumatoid arthritis. Rheumatology 43(Suppl 3):iii10-iii16. http://dx.doi.org/10.1093/rheumatology/keh202.
31. de la Mata J, Uy HL, Guise TA, Story B, Boyce BF, Mundy GR, Roodman GD. 1995. Interleukin-6 enhances hypercalcemia and bone resorption mediated by parathyroid hormone-related protein in vivo. J Clin Invest 95:2846-2852. http://dx.doi.org/10.1172/JCI117990.
32. Schett G. 2011. Effects of inflammatory and anti-inflammatory cytokines on the bone. Eur J Clin Invest 41:1361-1366. http://dx.doi.org/10.1111/j.1365-2362.2011.02545.x.
33. Cusick T, Chen CM, Pennypacker BL, Pickarski M, Kimmel DB, Scott BB, Duong LT. 2012. Odanacatib treatment increases hip bone mass and cortical thickness by preserving endocortical bone formation and stimulating periosteal bone formation in the ovariectomized adult rhesus monkey. J Bone Mineral Res 27:524-537. http://dx.doi.org/10.1002/jbmr.1477.
34. Cochran DL. 2008. Inflammation and bone loss in periodontal disease. J Periodontol 79:1569-1576. http://dx.doi.org/10.1902/jop.2008.080233.
35. Metzger Z. 2000. Macrophages in periapical lesions. Endod Dent Traumatol 16:1-8. http://dx.doi.org/10.1034/j.1600-9657.2000.016001001.x.
36. Ueda H, Howson JMM, Esposito L, Heward J, Snook Chamberlain G, Rainbow DB, Hunter KMD, Smith AN, Di Genova G, Herr MH, Dahlman I, Payne F, Smyth D, Lowe C, Twells RCJ, Howlett S, Healy B, Nutland S, Rance HE, Everett V, Smink LJ, Lam AC, Cordell HJ, Walker NM, Bordin C, Hulme J, Motzo C, Cucca F, Hess JF, Metzker ML, Rogers J, Gregory S, Allahabadia A, Nithiyananthan R, Tuomilehto-Wolf E, Tuomilehto J, Bingley P, Gillespie KM, Undlien DE, Ronningen KS, Guja C, Ionescu-Tirgoviste C, Savage DA, Maxwell AP, Carson DJ, Patterson CC, Franklyn JA, Clayton DG, Peterson LB, Wicker LS, Todd JA, Gough SCL. 2003. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 423:506-511. http://dx.doi.org/10.1038/nature01621.
37. Marçal JRB, Samuel RO, Fernandes D, de Araujo MS, Napimoga MH, Pereira SAL, Clemente-Napimoga JT, Alves PM, Mattar R, Rodrigues V, Jr, Rodrigues DBR. 2010. T-helper cell type 17/regulatory T-cell immunoregulatory balance in human radicular cysts and periapical granulomas. J Endod 36:995-999. http://dx.doi.org/10.1016/j.joen.2010.03.020.
38. Ataoglu T, Ungor M, Serpek B, Haliloglu S, Ataoglu H, Ari H. 2002. Interleukin-1beta and tumour necrosis factor-alpha levels in periapical exudates. Int Endod J 35:181-185. http://dx.doi.org/10.1046/j.1365-2591.2002.00467.x.
39. Beutler B, Cerami A. 1989. The biology of cachectin/TNF-α primary mediator of the host response. Annu Rev Immunol 7:625-655. http://dx.doi.org/10.1146/annurev.iy.07.040189.003205.
40. Gabay C. 2006. Interleukin-6 and chronic inflammation. Arthritis Res Ther 8(Suppl 2):S3. http://dx.doi.org/10.1186/ar1917.
41. Beutler B. 2004. Inferences, questions and possibilities in Toll-like receptor signalling. Nature 430:257-263. http://dx.doi.org/10.1038/nature02761.
42. Beklen A, Hukkanen M, Richardson R, Konttinen YT. 2008. Immunohistochemical localization of Toll-like receptors 1-10 in periodontitis. Oral Microbiol Immunol 23:425-431. http://dx.doi.org/10.1111/j.1399-302X.2008.00448.x.
43. Hirabara S, Kojima T, Takahashi N, Hanabayashi M, Ishiguro N. 2013. Hyaluronan inhibits TLR-4 dependent cathepsin K and matrix metalloproteinase 1 expression in human fibroblasts. Biochem Biophys Res Commun 430:519-522. http://dx.doi.org/10.1016/j.bbrc.2012.12.003.
44. Hirai T, Kanda T, Sato K, Takaishi M, Nakajima K, Yamamoto M, Kamijima R, Digiovanni J, Sano S. 2013. Cathepsin K is involved in development of psoriasis-like skin lesions through TLR-dependent Th17 activation. J Immunol 190:4805-4811. http://dx.doi.org/10.4049/jimmunol.1200901.